Literature DB >> 19535451

Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen.

Jorge Reyes-del Valle1, Gregory Hodge, Michael B McChesney, Roberto Cattaneo.   

Abstract

The widely used hepatitis B virus (HBV) vaccine is based on three doses of hepatitis B surface antigen (HBsAg) protein. We previously showed that vectored measles viruses (MV) expressing HBsAg retain measles vaccine function in monkeys but do not induce a protective anti-HBs response in all animals. We show here that a single dose of HBsAg protein following a three-dose vaccination regimen with an optimized HBsAg-expressing MV elicits protective anti-HBs responses in all four vaccinated Rhesus monkeys. Vaccination strategies coupling the effective, long-term immunity elicited by the high-coverage MV vaccine to prophylactic HBV immunity are discussed.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19535451      PMCID： PMC2738202          DOI： 10.1128/JVI.00906-09

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  23 in total

1.  A comparison of two commercial recombinant vaccines for hepatitis B in adolescents.

Authors:  G Leroux-Roels; B Abraham; M Fourneau; N De Clercq; A Safary
Journal:  Vaccine       Date:  2000-11-22       Impact factor: 3.641

Review 2.  Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues.

Authors:  Robert P Pless; Adwoa D Bentsi-Enchill; Philippe Duclos
Journal:  J Infect Dis       Date:  2003-05-15       Impact factor: 5.226

3.  Hepatitis B vaccines.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2004-07-09

4.  DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines.

Authors:  H L Davis; M J McCluskie; J L Gerin; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  Incremental system costs of introducing combined DTwP-hepatitis B-Hib vaccine into national immunization services in Ethiopia.

Authors:  Ulla K Griffiths; Viola S Korczak; Dereje Ayalew; Asnakew Yigzaw
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

6.  Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus.

Authors:  M D Lubeck; A R Davis; M Chengalvala; R J Natuk; J E Morin; K Molnar-Kimber; B B Mason; B M Bhat; S Mizutani; P P Hung
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

7.  Assessment of a universal, school-based hepatitis B vaccination program.

Authors:  S Dobson; D Scheifele; A Bell
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

Review 8.  Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B.

Authors:  Gillian M Keating; Stuart Noble
Journal:  Drugs       Date:  2003       Impact factor: 9.546

9.  Live recombinant vaccinia virus protects chimpanzees against hepatitis B.

Authors:  B Moss; G L Smith; J L Gerin; R H Purcell
Journal:  Nature       Date:  1984 Sep 6-11       Impact factor: 49.962

10.  Rescue of measles viruses from cloned DNA.

Authors:  F Radecke; P Spielhofer; H Schneider; K Kaelin; M Huber; C Dötsch; G Christiansen; M A Billeter
Journal:  EMBO J       Date:  1995-12-01       Impact factor: 11.598
View more
  17 in total

1.  A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Authors:  Melissa A Cobleigh; Linda Buonocore; Susan L Uprichard; John K Rose; Michael D Robek
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

2.  Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice.

Authors:  Yuan Hong; Yibing Peng; Michael Mi; Haiyan Xiao; David H Munn; Gui-Qiang Wang; Yukai He
Journal:  Vaccine       Date:  2011-03-21       Impact factor: 3.641

3.  Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.

Authors:  Ianko D Iankov; Iana H Haralambieva; Evanthia Galanis
Journal:  Vaccine       Date:  2010-12-21       Impact factor: 3.641

4.  Generation of a More Immunogenic Measles Vaccine by Increasing Its Hemagglutinin Expression.

Authors:  Emily Julik; Jorge Reyes-Del Valle
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

5.  Feasibility of Hepatitis B Vaccination by Microneedle Patch: Cellular and Humoral Immunity Studies in Rhesus Macaques.

Authors:  Youkyung H Choi; Monica B Perez-Cuevas; Maja Kodani; Xiugen Zhang; Mark R Prausnitz; Saleem Kamili; Siobhan M O'Connor
Journal:  J Infect Dis       Date:  2019-11-06       Impact factor: 5.226

6.  A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys.

Authors:  Patricia Devaux; Andrew W Hudacek; Gregory Hodge; Jorge Reyes-Del Valle; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

7.  Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster.

Authors:  Jorge Reyes-del Valle; Cynthia de la Fuente; Mallory A Turner; Christoph Springfeld; Swapna Apte-Sengupta; Marie E Frenzke; Amelie Forest; Jillian Whidby; Joseph Marcotrigiano; Charles M Rice; Roberto Cattaneo
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 8.  Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave.

Authors:  Brenna Sharp; Ramya Rallabandi; Patricia Devaux
Journal:  Mol Diagn Ther       Date:  2022-06-28       Impact factor: 4.476

9.  Measles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys.

Authors:  Vincent H J Leonard; Gregory Hodge; Jorge Reyes-Del Valle; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Authors:  Hoyin Mok; Xing Cheng; Qi Xu; James R Zengel; Bandita Parhy; Jackie Zhao; C Kathy Wang; Hong Jin
Journal:  Open Virol J       Date:  2012-02-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.